Literature DB >> 8688195

Role of retinoic acid receptor gamma in the Rhino mouse and rabbit irritation models of retinoid activity.

P R Reczek1, J Ostrowski, K L Yu, S Chen, L Hammer, T Roalsvig, J E Starrett, J P Driscoll, G Whiting, P G Spinazze.   

Abstract

The three retinoic acid receptors (RAR alpha, RAR beta and RAR gamma) are known to modulate the transcription of target genes through interaction of the individual receptors with their naturally occurring ligand, retinoic acid (RA). Since RA has multiple effects in vivo, considerable effort has recently been devoted to finding selective compounds to elucidate the functions of individual receptors and to relate these functions to specific in vivo effects. The racemic synthetic retinoid 6-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)hydroxy-methyl]-2- naphthalene carboxylic acid has recently been identified as an RAR gamma-selective agonist. A synthetic method involving lipase-mediated transformation has been developed to prepare the individual enantiomers. Discrimination between the two enantiomers is seen in both transcriptional activity and binding to recombinant receptors with the (S)-enantiomer being the more active. Differences between the two compounds are also seen in the Rhino mouse utriculi reduction assay and the rabbit irritation model. In both animal models, the (S)-enantiomer consistently gave a greater response. Taken together, these results suggest that the activity and irritation seen with RA and related compounds is receptor mediated. Further, the strong selectivity of the compounds reported here for RAR gamma suggests that this receptor plays an important role in these in vivo biological activities. The discrimination between these enantiomers may be useful in the design of novel retinoids with uniquely defined biological properties.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8688195     DOI: 10.1159/000211360

Source DB:  PubMed          Journal:  Skin Pharmacol        ISSN: 1011-0283


  2 in total

1.  Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRARgamma.

Authors:  B P Klaholz; A Mitschler; M Belema; C Zusi; D Moras
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 2.  Towards retinoid therapy for Alzheimer's disease.

Authors:  K Shudo; H Fukasawa; M Nakagomi; N Yamagata
Journal:  Curr Alzheimer Res       Date:  2009-06       Impact factor: 3.498

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.